Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Rojas-Marcos
I
I
Fédération de Neurologie Mazarin and INSERM U 495, Hôpital de la Salpêtrière, AP-HP, Paris, France.
Calvet
D
D
Janoray
P
P
Delattre
J Y
JY
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016190:Carboplatin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D019583:Dose Fractionation, Radiation; D004806:Ependymoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005682:Gadolinium; D006261:Headache / Q000209:etiology; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local; D012074:Remission Induction; D013629:Tamoxifen / Q000008:administration & dosage; D000077204:Temozolomide; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D013629:Tamoxifen; D003606:Dacarbazine; D005682:Gadolinium; D016190:Carboplatin; D015474:Isotretinoin; D002330:Carmustine; D000077204:Temozolomide